/UPB
UPB Stock - Upstream Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$29.35-1.71%
$0.51 (-1.71%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.45
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+67.0%upside
Target: $49.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for UPB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$29.06 – $29.64
TARGET (TP)$49.00
STOP LOSS$27.00
RISK/REWARD1:8.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.86
52W High$33.00
52W Low$5.14
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $2.37M | $2.38M | $1.21M |
| Gross Profit | $2.37M | $2.38M | $1.21M |
| Gross Margin | 100.0% | 100.0% | 100.0% |
| Operating Income | $-77,764,000 | $-40,114,000 | $-23,909,000 |
| Net Income | $-62,806,000 | $-20,537,000 | $-23,868,000 |
| Net Margin | -2650.0% | -862.9% | -1969.3% |
| EPS | $-1.49 | $-1.05 | $-0.66 |
Company Overview
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$50
Average Target
↑ 71.0% Upside
Now
$38
Low
$50
Average
$75
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | Mizuho | Initiation | Outperform | $51 |
| November 18th 2025 | Evercore ISI | Initiation | Outperform | $40 |
| October 14th 2025 | Truist | Initiation | Buy | $47 |
| November 5th 2024 | Piper Sandler | Initiation | Overweight | $75 |
| November 5th 2024 | JP Morgan | Initiation | Overweight | $38 |
| November 5th 2024 | William Blair | Initiation | Outperform | - |
| November 5th 2024 | TD Cowen | Initiation | Buy | - |
Earnings History & Surprises
UPBBeat Rate
20%
Last 5 quarters
Avg Surprise
-278.1%
EPS vs Estimate
Beats / Misses
1/4
Last 12 quarters
Latest EPS
$-0.63
Q4 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q4 24
-1200.3%
$-6.96vs$-0.54
Q1 25
-183.9%
$-1.59vs$-0.56
Q2 25
-4.1%
$-0.51vs$-0.49
Q3 25
-21.3%
$-0.74vs$-0.61
Q4 25
+19.2%
$-0.63vs$-0.78
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 11, 2026 | $-0.75 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.78 | $-0.63 | +19.2% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.61 | $-0.74 | -21.3% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.49 | $-0.51 | -4.1% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.56 | $-1.59 | -183.9% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.54 | $-6.96 | -1200.3% | ✗ MISS |
Q4 2024 | Oct 11, 2024 | — | — | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.14 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.09 | — | — |
Latest News
Mizuho Initiates Coverage On Upstream Bio with Outperform Rating, Announces Price Target of $51
📈 PositiveBenzinga•Dec 18, 2025, 09:36 AM
LifeSci Capital Initiates Coverage On Upstream Bio with Outperform Rating, Announces Price Target of $43
📈 PositiveBenzinga•Dec 2, 2025, 12:54 PM
Evercore ISI Group Initiates Coverage On Upstream Bio with Outperform Rating, Announces Price Target of $40
📈 PositiveBenzinga•Nov 18, 2025, 12:39 PM
Upstream Bio Q3 EPS $(0.63) Beats $(0.76) Estimate, Sales $683.000K Beat $645.000K Estimate
📈 PositiveBenzinga•Nov 5, 2025, 12:16 PM
Truist Securities Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $47
📈 PositiveBenzinga•Oct 14, 2025, 01:09 PM
Upstream Bio Highlights New Respiratory Drug Verekitug With Trial Data
📈 PositiveBenzinga•Sep 30, 2025, 08:26 AM
Upstream Bio Reports Positive Phase 2 VIBRANT Trial Results For Verekitug In Chronic Rhinosinusitis With Nasal Polyps, Meeting Primary And Secondary Endpoints With Favorable Safety Profile
📈 PositiveBenzinga•Sep 2, 2025, 10:09 AM
Frequently Asked Questions about UPB
What is UPB's current stock price?
Upstream Bio, Inc. (UPB) is currently trading at $29.35 per share. The stock has moved -1.71% today.
What is the analyst price target for UPB?
The average analyst price target for UPB is $49.00, based on 1 analyst.
What sector is Upstream Bio, Inc. in?
Upstream Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is UPB's market cap?
Upstream Bio, Inc. has a market capitalization of $1.59 billion, making it a small-cap company.
Does UPB pay dividends?
No, Upstream Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMLX
Amylyx Pharmaceuticals, Inc.
$12.02
Mkt Cap: $1.0B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
NVAX
Novavax, Inc.
$6.66
Mkt Cap: $1.1B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
TERN
Terns Pharmaceuticals, Inc.
$39.90
Mkt Cap: $3.6B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
ZBIO
Zenas BioPharma, Inc.
$36.15
Mkt Cap: $1.5B
Explore stocks similar to UPB for comparison